Precision BioSciences (DTIL)
(Real Time Quote from BATS)
$10.02 USD
-0.36 (-3.47%)
Updated Jul 17, 2024 02:20 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DTIL 10.02 -0.36(-3.47%)
Will DTIL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DTIL
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
Other News for DTIL
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
Precision BioSciences appoints Sulkowski, Feld to Hepatitis SAB
Precision BioSciences: Governance Updates and Growth Strategy